Neogen Corporation (NEOG)
NEOG Stock Price Chart
Explore Neogen Corporation interactive price chart. Choose custom timeframes to analyze NEOG price movements and trends.
NEOG Company Profile
Discover essential business fundamentals and corporate details for Neogen Corporation (NEOG) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
23 Aug 1989
Employees
2.92K
Website
https://www.neogen.comCEO
John Edward Adent
Description
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed producers and processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
NEOG Financial Timeline
Browse a chronological timeline of Neogen Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 Apr 2026
Upcoming earnings on 8 Jan 2026
Upcoming earnings on 9 Oct 2025
EPS estimate is $0.05, while revenue estimate is $203.93M.
Earnings released on 29 Jul 2025
EPS came in at $0.05 falling short of the estimated $0.08 by -37.50%, while revenue for the quarter reached $225.46M , beating expectations by +11.25%.
Earnings released on 9 Apr 2025
EPS came in at $0.10 falling short of the estimated $0.13 by -23.08%, while revenue for the quarter reached $220.98M , missing expectations by -0.70%.
Earnings released on 10 Jan 2025
EPS came in at $0.11 surpassing the estimated $0.09 by +22.22%, while revenue for the quarter reached $231.26M , beating expectations by +1.40%.
Earnings released on 10 Oct 2024
EPS came in at $0.07 falling short of the estimated $0.09 by -17.65%, while revenue for the quarter reached $216.96M , beating expectations by +0.89%.
Earnings released on 30 Jul 2024
EPS came in at $0.10 falling short of the estimated $0.12 by -16.67%, while revenue for the quarter reached $236.79M , beating expectations by +4.85%.
Earnings released on 9 Apr 2024
EPS came in at $0.12 falling short of the estimated $0.14 by -14.29%, while revenue for the quarter reached $228.81M , missing expectations by -2.94%.
Earnings released on 9 Jan 2024
EPS came in at $0.11 falling short of the estimated $0.15 by -26.67%, while revenue for the quarter reached $229.63M , missing expectations by -1.39%.
Earnings released on 10 Oct 2023
EPS came in at $0.11 falling short of the estimated $0.14 by -21.43%, while revenue for the quarter reached $228.99M , missing expectations by -0.91%.
Earnings released on 27 Jul 2023
EPS came in at $0.14 surpassing the estimated $0.10 by +40.00%, while revenue for the quarter reached $241.81M , beating expectations by +6.22%.
Earnings released on 30 Mar 2023
EPS came in at $0.12 surpassing the estimated $0.03 by +366.74%, while revenue for the quarter reached $218.26M , missing expectations by -0.28%.
Earnings released on 5 Jan 2023
EPS came in at $0.15 surpassing the estimated -$0.08 by +287.50%, while revenue for the quarter reached $230.03M , beating expectations by +0.76%.
Earnings released on 27 Sept 2022
EPS came in at $0.15 falling short of the estimated $0.16 by -6.25%, while revenue for the quarter reached $132.35M , missing expectations by -2.51%.
Earnings released on 26 Jul 2022
EPS came in at $0.14 surpassing the estimated $0.12 by +16.67%, while revenue for the quarter reached $140.09M , beating expectations by +1.25%.
Earnings released on 24 Mar 2022
EPS came in at $0.13 falling short of the estimated $0.15 by -13.33%, while revenue for the quarter reached $128.24M , missing expectations by -1.35%.
Earnings released on 21 Dec 2021
EPS came in at $0.17 matching the estimated $0.17, while revenue for the quarter reached $130.52M , beating expectations by +0.41%.
Earnings released on 21 Sept 2021
EPS came in at $0.16 matching the estimated $0.16, while revenue for the quarter reached $128.31M , beating expectations by +7.14%.
Earnings released on 20 Jul 2021
EPS came in at $0.15 falling short of the estimated $0.17 by -11.76%, while revenue for the quarter reached $127.43M , beating expectations by +5.14%.
Stock split effective on 7 Jun 2021
Shares were split 2 : 1 , changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 4 Jun 2021
Shares were split 2 : 1 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 23 Mar 2021
EPS came in at $0.13 matching the estimated $0.13, while revenue for the quarter reached $116.71M , beating expectations by +9.33%.
Earnings released on 22 Dec 2020
EPS came in at $0.15 falling short of the estimated $0.16 by -6.25%, while revenue for the quarter reached $115.00M , missing expectations by -5.88%.
Earnings released on 22 Sept 2020
EPS came in at $0.15 surpassing the estimated $0.14 by +7.14%, while revenue for the quarter reached $109.33M , beating expectations by +7.14%.
NEOG Stock Performance
Access detailed NEOG performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.